Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving internal radiation therapy using a special radiation therapy device may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well internal radiation therapy after lumpectomy works in treating women with ductal carcinoma in situ.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Masonic Cancer Center, University of Minnesota
• Treatments: Tamoxifen

Criteria

Inclusion Criteria:

• Ductal carcinoma in situ (DCIS) confirmed by excisional or needle biopsy

• Size: < 3 cm on mammogram

• Unicentric disease

• Ability to place MammoSite device at time of lumpectomy or within 4 weeks of lumpectomy

• Patient Age: ≥ 18 years, no upper limit

• Life expectancy > 5 years

Exclusion Criteria:

• Prior history of cancer other than basal or squamous cell skin cancer or in situ cancer of the cervix

• Pregnant or breast feeding

• Multicentric disease

• Diagnosis of collagen vascular diseases, such as systemic lupus erythematosis, scleroderma, or dermatomyositis